Your browser doesn't support javascript.
loading
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.
García-Domínguez, Daniel J; Hontecillas-Prieto, Lourdes; Palazón-Carrión, Natalia; Jiménez-Cortegana, Carlos; Sánchez-Margalet, Víctor; de la Cruz-Merino, Luis.
Afiliação
  • García-Domínguez DJ; Clinical Laboratory, Department of Medical Biochemistry and Molecular Biology, School of Medicine, University of Seville, Virgen Macarena University Hospital, 41009 Seville, Spain.
  • Hontecillas-Prieto L; Oncology Service, Virgen Macarena University Hospital, Department of Medicines, School of Medicine, University of Seville, 41009 Seville, Spain.
  • Palazón-Carrión N; Clinical Laboratory, Department of Medical Biochemistry and Molecular Biology, School of Medicine, University of Seville, Virgen Macarena University Hospital, 41009 Seville, Spain.
  • Jiménez-Cortegana C; Oncology Service, Virgen Macarena University Hospital, Department of Medicines, School of Medicine, University of Seville, 41009 Seville, Spain.
  • Sánchez-Margalet V; Oncology Service, Virgen Macarena University Hospital, Department of Medicines, School of Medicine, University of Seville, 41009 Seville, Spain.
  • de la Cruz-Merino L; Clinical Laboratory, Department of Medical Biochemistry and Molecular Biology, School of Medicine, University of Seville, Virgen Macarena University Hospital, 41009 Seville, Spain.
Cancers (Basel) ; 14(6)2022 Mar 13.
Article em En | MEDLINE | ID: mdl-35326620
ABSTRACT
Lymphoma is a neoplasm arising from B or T lymphocytes or natural killer cells characterized by clonal lymphoproliferation. This tumor comprises a diverse and heterogeneous group of malignancies with distinct clinical, histopathological, and molecular characteristics. Despite advances in lymphoma treatment, clinical outcomes of patients with relapsed or refractory disease remain poor. Thus, a deeper understanding of molecular pathogenesis and tumor progression of lymphoma is required. Epigenetic alterations contribute to cancer initiation, progression, and drug resistance. In fact, over the past decade, dysregulation of epigenetic mechanisms has been identified in lymphomas, and the knowledge of the epigenetic aberrations has led to the emergence of the promising epigenetic therapy field in lymphoma tumors. However, epigenetic aberrations in lymphoma not only have been found in tumor cells, but also in cells from the tumor microenvironment, such as immune cells. Whereas the epigenetic dysregulation in lymphoma cells is being intensively investigated, there are limited studies regarding the epigenetic mechanisms that affect the functions of immune cells from the tumor microenvironment in lymphoma. Therefore, this review tries to provide a general overview of epigenetic alterations that affect both lymphoma cells and infiltrating immune cells within the tumor, as well as the epigenetic cross-talk between them.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article